Cervical cancer chemo easier on black women: study
Key points
- Black women with advanced and recurrent cervical cancer tolerate "platinum-based" chemotherapy drugs better than do their white counterparts, according to a pooled data from three studies, researchers report.
- Plaxe of the University of California, San Diego and colleagues examined data on a total of 374 white and 125 black women who were treated with a variety of chemotherapy drug combinations that included cisplatin - a platinum-based drug commonly used to fight various cancers.
- The researchers found that black women had significantly less moderate to severe neutropenia (63 percent) than did whites (82 percent).
- Two other chemotherapy-related side effects - leukopenia (an abnormally low white blood cell count) and thrombocytopenia (a reduction in blood clotting platelet cells) were also less common in black women than in white women.
Black women with advanced and recurrent cervical cancer tolerate "platinum-based" chemotherapy drugs better than do their white counterparts, according to a pooled data from three studies, researchers report.
Dr. Steven C. Plaxe of the University of California, San Diego and colleagues examined data on a total of 374 white and 125 black women who were treated with a variety of chemotherapy drug combinations that included cisplatin - a platinum-based drug commonly used to fight various cancers.
The researchers found that black women had significantly less moderate to severe neutropenia (63 percent) than did whites (82 percent). Neutropenia is a condition characterized by a drop in a particular type of infection-fighting white blood cell called the neutrophil that can occur with frequent chemotherapy.
Two other chemotherapy-related side effects - leukopenia (an abnormally low white blood cell count) and thrombocytopenia (a reduction in blood clotting platelet cells) were also less common in black women than in white women.
Moreover, compared to white women, black women were not at increased risk of having their disease get worse or of dying from their disease, the study team reports in the American Journal of Obstetrics and Gynecology.
"Our results," Plaxe told Reuters Health, "support efforts directed at encouraging enrollment of all eligible women, particularly minorities, into clinical research studies."
SOURCE: American Journal of Obstetrics and Gynecology, November 2008.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsCurrent guidelines underestimate US cervical cancer incidence and older women's risk
Rates of cervical cancer in American women may be higher than previously thought, and the disease may arise most often at an age when adequately screened women are advised to stop getting screened. The findings come…
12 May 2014
NewsReceiving chemotherapy after a breast cancer diagnosis may affect a patient's employment
A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, a…
28 April 2014
NewsAn easier, safer, and more accurate treatment for pancreatic cancer
Using CT scans with contrast enhancement, Dartmouth researchers measured treatment response to pancreatic cancer photodynamic therapy (PDT) according to a paper published in Physics in Medicine and Biology. The research…
